{"downloaded": true, "htmlmade": false, "full": {"id": "29724899", "source": "MED", "pmid": "29724899", "pmcid": "PMC6265654", "fullTextIdList": {"fullTextId": "PMC6265654"}, "doi": "10.1182/blood-2017-12-818948", "title": "The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.", "authorString": "Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, L\u00f6wenberg B, Tallman MS.", "authorList": {"author": [{"fullName": "Stein EM", "firstName": "Eytan M", "lastName": "Stein", "initials": "EM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Garcia-Manero G", "firstName": "Guillermo", "lastName": "Garcia-Manero", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX."}}}, {"fullName": "Rizzieri DA", "firstName": "David A", "lastName": "Rizzieri", "initials": "DA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Duke University Medical Center, Durham, NC."}}}, {"fullName": "Tibes R", "firstName": "Raoul", "lastName": "Tibes", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Mayo Clinic Scottsdale Arizona, Scottsdale, AZ."}}}, {"fullName": "Berdeja JG", "firstName": "Jesus G", "lastName": "Berdeja", "initials": "JG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Sarah Cannon Research Institute, Nashville, TN."}}}, {"fullName": "Savona MR", "firstName": "Michael R", "lastName": "Savona", "initials": "MR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN."}}}, {"fullName": "Jongen-Lavrenic M", "firstName": "Mojca", "lastName": "Jongen-Lavrenic", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Erasmus University Medical Center, Rotterdam, The Netherlands."}}}, {"fullName": "Altman JK", "firstName": "Jessica K", "lastName": "Altman", "initials": "JK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL."}}}, {"fullName": "Thomson B", "firstName": "Blythe", "lastName": "Thomson", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "Blakemore SJ", "firstName": "Stephen J", "lastName": "Blakemore", "initials": "SJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "Daigle SR", "firstName": "Scott R", "lastName": "Daigle", "initials": "SR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "Waters NJ", "firstName": "Nigel J", "lastName": "Waters", "initials": "NJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "Suttle AB", "firstName": "A Benjamin", "lastName": "Suttle", "initials": "AB", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "Clawson A", "firstName": "Alicia", "lastName": "Clawson", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "Pollock R", "firstName": "Roy", "lastName": "Pollock", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "Krivtsov A", "firstName": "Andrei", "lastName": "Krivtsov", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute, Boston, MA; and."}}}, {"fullName": "Armstrong SA", "firstName": "Scott A", "lastName": "Armstrong", "initials": "SA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute, Boston, MA; and."}}}, {"fullName": "DiMartino J", "firstName": "Jorge", "lastName": "DiMartino", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Celgene, San Francisco, CA."}}}, {"fullName": "Hedrick E", "firstName": "Eric", "lastName": "Hedrick", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Epizyme, Inc., Cambridge, MA."}}}, {"fullName": "L\u00f6wenberg B", "firstName": "Bob", "lastName": "L\u00f6wenberg", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Erasmus University Medical Center, Rotterdam, The Netherlands."}}}, {"fullName": "Tallman MS", "firstName": "Martin S", "lastName": "Tallman", "initials": "MS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "24", "volume": "131", "journalIssueId": "2696969", "dateOfPublication": "2018 Jun", "monthOfPublication": "6", "yearOfPublication": "2018", "printPublicationDate": "2018-06-01", "journal": {"title": "Blood", "ISOAbbreviation": "Blood", "medlineAbbreviation": "Blood", "NLMid": "7603509", "ISSN": "0006-4971", "ESSN": "1528-0020"}}, "pubYear": "2018", "pageInfo": "2661-2669", "abstractText": "Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involving mixed lineage leukemia (<i>MLL</i>) gene rearrangements (<i>MLL-r</i>) resulting from 11q23 translocations. Fifty-one patients were enrolled into 6 dose-escalation cohorts (n = 26) and 2 expansion cohorts (n = 25) at pinometostat doses of 54 and 90 mg/m<sup>2</sup> per day by continuous intravenous infusion in 28-day cycles. Because a maximum tolerated dose was not established in the dose-escalation phase, the expansion doses were selected based on safety and clinical response data combined with pharmacodynamic evidence of reduction in H3K79 methylation during dose escalation. Across all dose levels, plasma pinometostat concentrations increased in an approximately dose-proportional fashion, reaching an apparent steady-state by 4-8 hours after infusion, and rapidly decreased following treatment cessation. The most common adverse events, of any cause, were fatigue (39%), nausea (39%), constipation (35%), and febrile neutropenia (35%). Overall, 2 patients, both with t(11;19), experienced complete remission at 54 mg/m<sup>2</sup> per day by continuous intravenous infusion, demonstrating proof of concept for delivering clinically meaningful responses through targeting DOT1L using the single agent pinometostat in <i>MLL-r</i> leukemia patients. Administration of pinometostat was generally safe, with the maximum tolerated dose not being reached, although efficacy as a single agent was modest. This study demonstrates the therapeutic potential for targeting DOT1L in <i>MLL-r</i> leukemia and lays the groundwork for future combination approaches in this patient population. This clinical trial is registered at www.clinicaltrials.gov as NCT01684150.", "affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "P30 CA008748", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P01 CA066996", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Benzimidazoles", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Methyltransferases", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Histone-Lysine N-Methyltransferase"}, {"majorTopic_YN": "N", "descriptorName": "Histones", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Methylation", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}]}, "chemicalList": {"chemical": [{"name": "DOT1L protein, human", "registryNumber": "EC 2.1.1.-"}, {"name": "Antineoplastic Agents", "registryNumber": "0"}, {"name": "Benzimidazoles", "registryNumber": "0"}, {"name": "Histones", "registryNumber": "0"}, {"name": "Histone-Lysine N-Methyltransferase", "registryNumber": "EC 2.1.1.43"}, {"name": "Methyltransferases", "registryNumber": "EC 2.1.1.-"}, {"name": "EPZ-5676", "registryNumber": "0"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2017-12-818948"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6265654"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2017-12-818948"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "N", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "91", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-07-08", "dateOfCreation": "2018-05-05", "firstIndexDate": "2018-05-05", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2021-02-02", "electronicPublicationDate": "2018-05-03", "firstPublicationDate": "2018-05-03", "embargoDate": "2019-06-14"}, "abstract": "Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involving mixed lineage leukemia (<i>MLL</i>) gene rearrangements (<i>MLL-r</i>) resulting from 11q23 translocations. Fifty-one patients were enrolled into 6 dose-escalation cohorts (n = 26) and 2 expansion cohorts (n = 25) at pinometostat doses of 54 and 90 mg/m<sup>2</sup> per day by continuous intravenous infusion in 28-day cycles. Because a maximum tolerated dose was not established in the dose-escalation phase, the expansion doses were selected based on safety and clinical response data combined with pharmacodynamic evidence of reduction in H3K79 methylation during dose escalation. Across all dose levels, plasma pinometostat concentrations increased in an approximately dose-proportional fashion, reaching an apparent steady-state by 4-8 hours after infusion, and rapidly decreased following treatment cessation. The most common adverse events, of any cause, were fatigue (39%), nausea (39%), constipation (35%), and febrile neutropenia (35%). Overall, 2 patients, both with t(11;19), experienced complete remission at 54 mg/m<sup>2</sup> per day by continuous intravenous infusion, demonstrating proof of concept for delivering clinically meaningful responses through targeting DOT1L using the single agent pinometostat in <i>MLL-r</i> leukemia patients. Administration of pinometostat was generally safe, with the maximum tolerated dose not being reached, although efficacy as a single agent was modest. This study demonstrates the therapeutic potential for targeting DOT1L in <i>MLL-r</i> leukemia and lays the groundwork for future combination approaches in this patient population. This clinical trial is registered at www.clinicaltrials.gov as NCT01684150.", "journaltitle": "Blood", "authorinfo": ["Stein EM", "Garcia-Manero G", "Rizzieri DA", "Tibes R", "Berdeja JG", "Savona MR", "Jongen-Lavrenic M", "Altman JK", "Thomson B", "Blakemore SJ", "Daigle SR", "Waters NJ", "Suttle AB", "Clawson A", "Pollock R", "Krivtsov A", "Armstrong SA", "DiMartino J", "Hedrick E", "L\u00f6wenberg B", "Tallman MS"], "title": "The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia."}